-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Sunshine
August 12, CDE official website shows, GlaxoSmithKline antisense oligonucleotides GSK3228836 injection drugs in clinical trials apply the State Food and Drug Administration approval for the treatment of chronic hepatitis
Source: PharmaGo
Chronic hepatitis B is a chronic disease in which hepatitis B virus (HBV) continues to be infected for more than 6 months, and the liver undergoes varying degrees of inflammatory necrosis (or) fibrosis
Nucleoside and nucleoside analog drugs currently used to treat hepatitis B can inhibit the hepatitis B virus, but cannot completely remove the virus from the body
GSK3228836 is an antisense oligonucleotide that can specifically recognize the mRNA used to express viral antigens (pathogenic proteins) in liver cells infected with HBV, and inactivate viral mRNAs by mobilizing the liver’s own enzymes to inhibit viral proteins HBsAg levels in order to achieve the functional purpose of curing hepatitis B